I spoke by phone this morning with "Mike," a long-time pharma professional who's at a crossroads in his career. Like many in the industry, Mike sees the overall economy improving and his company, a growing biopharma, doing the right things to move ahead. And yet, for the most part, he's stuck.
The contentious negotiations between Bayer and the 400 or so unionized workers at its Berkeley, California biotech facility have become a test case for whether workers in pharma/biopharma (and other industries) have any leverage whatsoever in the face of potential or expected downsizing and outsourcing.
We've just published, in print and online, our latest cover story: “The Good Fight: The Plight of Pharma’s Middle Managers.” It’s a rich, timely topic, given the fact that much of the finger pointing regarding the industry's problems is aimed at mid-level professionals.
Change management has become an important and accepted aspect of corporate success in recent years. Companies are beginning to understand that anticipating major change—whether it be in terms of products, processes, or people—and having a systematic methodology for handling it makes a lot of sense—to the stability of the organization...
Middle managers in the life sciences are underappreciated and underrated in their significance, and yet they're often the first individuals to be blamed for operational issues or to be laid off during restructurings.
Most of the U.S. Department of Justice’s major pharma-related decisions invoking the False Claims Act recently have involved illegal marketing and sales. So far, GSK’s is the only one to deal with current good manufacturing practices (cGMP’s).
Uberblogger Pharmagossip and the expert satirist Pharmagiles recently posted riffs inspired by the GSK whistleblower case, with Pharmagiles setting the lyrics to Harry Belafonte's famous Banana Boat Song. Click here for a view.
Did any of you catch that recent WSJ report on the negative impact of mass layoffs? OK, I know that M&A layoffs are different, but today brought the sad news that Pfizer/Wyeth will lay off 6,000 employees and close eight of its manufacturing plants in Ireland, Puerto Rico and the U.S.
The saga of KV Pharmaceutical provides a cautionary tale for any manufacturer who would overlook manufacturing quality issues and attempt to fly under the regulatory radar. As most in the industry know, KV has gone from a model growth company to one on the brink of bankruptcy, following manufacturing issues...